|PCSK9 Education and Research Forum:
New on PCSK9 Education and Research Forum
Inaugural Editorial Board Meeting: State-of-the-Art PCSK9 Science: Current understanding and therapeutic perspectives
From the Editor’s Desk
PCSK9 Education and Research Forum convened the first Editorial Board on 29th August, 2014 to discuss the state of PCSK9 science and ongoing challenges in this field.
Does PCSK9 have effects beyond the liver?
Professor Bertrand Cariou, INSERM UMR1087, l’Institut du Thorax, Nantes, France
PCSK9 loss of function mutations: mechanistic insights:
Professor Anne Tybjaerg-Hansen, Rigshospitalet, Copenhagen University Hospital, and University of Copenhagen, Denmark
How can we optimise PCSK9-targeted therapies?
A view from Europe: Professor Luis Masana, University Rovira and Virgili, Reus-Tarragona, Spain
A view from North America:
Professor Henry Ginsberg, Columbia University, New York, USA
Professor Matthew Ito comments on the new US NLA recommendations for management of dyslipidaemia.
Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite linkOur mission
PCSK9 Education and Research Forum is the major, globally-recognised resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Our mission is to facilitate development of these new treatments in order to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes.